WO2012140352A2 - Gleditsia composition for treating excess fat - Google Patents

Gleditsia composition for treating excess fat Download PDF

Info

Publication number
WO2012140352A2
WO2012140352A2 PCT/FR2012/050747 FR2012050747W WO2012140352A2 WO 2012140352 A2 WO2012140352 A2 WO 2012140352A2 FR 2012050747 W FR2012050747 W FR 2012050747W WO 2012140352 A2 WO2012140352 A2 WO 2012140352A2
Authority
WO
WIPO (PCT)
Prior art keywords
gleditsia
mucilage
composition
composition according
agent
Prior art date
Application number
PCT/FR2012/050747
Other languages
French (fr)
Other versions
WO2012140352A3 (en
Inventor
Nadine Leconte
Jacques Leclere
Original Assignee
Laboratoire Nuxe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Nuxe filed Critical Laboratoire Nuxe
Publication of WO2012140352A2 publication Critical patent/WO2012140352A2/en
Publication of WO2012140352A3 publication Critical patent/WO2012140352A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/483—Gleditsia (locust)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Definitions

  • the present invention relates to a novel cosmetic and / or dermatological composition with lipolytic property, and more particularly to a composition based on Gleditsia mucilage intended to treat and / or prevent fat overload and cellulite.
  • the skin is a real organ comprising a plurality of integrated layers, from super ficial ⁇ layer, the epidermis, to the deeper layers, the dermis and the hypodermis, and each has spe- cific properties allowing all to react and adapt to the conditions of its environment.
  • the epidermis composed mainly of keratinocytes (90% of epidermal cells), melanocytes (2 to 3% of epidermal cells) and Langerhans cells, has a variable thickness depending on the different parts of the body. Since it constitutes the outer layer of the skin, the epidermis plays a fundamental role in ensuring the protection and maintenance of good trophicity. This is why many compositions have been developed to protect and improve its functions, including strengthening its elasticity and firmness.
  • the dermis thicker, solid, rich in nerves, blood vessels and sweat glands, consists mainly of collagen, elastin and proteoglycans. These three types of molecules are synthesized by dermal fibroblasts. Collagen fibers, which repre ⁇ tent 70% of the dry weight of the dermis, ensure the mechanical strength and texture of the skin, elastin is responsible for the elasticity, and proteoglycans play a major role structure and hydration of the skin. Other cells such as macrophages and leucocytes are also present in the dermis layer.
  • hypodermis which is the deepest layer of skin, contains lipid-producing fat cells so that the subcutaneous tissue makes a fat layer that protects muscles, bones, and internal organs from shock.
  • Adipocytes synthesize triglycerides by lipogenesis from free fatty acids and glycerol from glucose degradation. Fatty acids and glucose are brought to the body by food. Conversely, the triglycerides contained in adipocytes undergo lipolysis by the action of enzymes and release glycerol or glycerol esters as well as fatty acids which can in turn circulate in the body and / or be captured by adipocytes. where they are again transformed into triglycerides by lipogenesis. Thus, in case of imbalance between lipogenesis and lipolysis, it can produce excessive accumu ⁇ lation triglycerides which results in excess adipose, or fat deposits localized.
  • Adipose overloads are defects that can affect the aesthetic appearance of the individual, and they also constitute abnormal physiological states in humans, but especially in women, where accumulations of cellulite are still considered unsightly. These fat overloads can also result in bags under the eyes and dark circles. These conditions, although different from obesity, usually require systemic treatment. Often, in the absence of therapeutic treatment, a cosmetic treatment is desired to fight against fat overload, and to mitigate the unsightly effects.
  • procyanidolic oligomers derived from grape seeds, flavonoids, such as ruscus, red vine extracts, horse chestnut, witch hazel have a certain circulatory drainage action.
  • Caffeine, and various caffeine derivatives can help reduce edema and fluid retention, increase lipolysis, and limit fat storage.
  • high concentration caffeine may cause side effects, such as palpitations, in some subjects.
  • its low solubility in water and alcohols is a disadvantage for the formulation of cosmetic compo ⁇ sions.
  • Gleditsia more specifically the species G. triacanthos, is a tree 20 to 30 m tall belonging to the family Fabaceae, native to North America. Its branches are adorned with simple or branched spines, its leaves, brilliant green in color turning yellow in autumn, are deciduous, doubly composed of leaflets bordered with rounded teeth.
  • the fruit of Gleditsia is a long, flattened pod in the shape of a scythe and containing from 10 to 20 seeds, drying on the tree before falling.
  • Gleditsia The genus Gleditsia includes many species and varieties existing in the world. The following species may be mentioned: Gleditsia triacanthos L. (or Gleditsia ferox), Gleditsia australis Hemsl. (still called Gleditsia will do Merr., Gleditsia sinensis or Gleditsia thorelii), Gleditsia africana Walv. (or Gleditsia africanum Harms.), Gleditsia japonica Micq., Gleditsia javanica Lam.
  • Gleditsia officinalis Hemsl. Gleditsia inermis, Gleditsia amorphoides, Gleditsia aquatica, Gleditsia capsica, Gleditsia delavayi, Gleditsia horrida, Gleditsia koraiensis, Gleditsia macracantha, Geditsia rolfei, Gleditsia texana.
  • Gleditsia contain a variety of useful substances, including triacanthine, which is found mainly in pods and leaves, which may contain about 100 mg / kg of triacanthine per kg of dry plant.
  • Triacanthine is a purine-derived alkaloid, analogous to that of kinetin, whose properties have been described by Beauchesne et al., Physiologia Plantarum, vol. 16 (1963). It has been shown to have hypotensive, cardiotonic and antispasmodic activity, with low toxicity, since its LD50 is of the order of 30 mg / kg, lower than that of caffeine. Its cardiotonic action in animals has been described by 0. Foussard-Blanpin et al., French Pharmaceutical Annals vol. 27, p. 257-259 (1969).
  • the patent application WO 2008009813 describes a composition comprising a Gleditsia extract and triacanthine having a lipolytic effect useful for the treatment of fat overload and cellulite.
  • Gleditsia seeds and mucilage contain practically no triacanthine.
  • Various parts of the plant also contain flavonoids, saponins (derived from catechin), and the seed mucilage is princi ⁇ palely rich in arabinose.
  • Gleditsia mucilage can be obtained by treatment of the seeds, for example by aqueous extraction in an acid medium, drying and mixing with maltodextrin to prevent caking of the powder.
  • the dry product obtained generally has a high content of polysaccharides.
  • the patent FR 1602259 describes the use of an aqueous mucilage extract of Gleditsia triacanthos seeds, treated to obtain a solution of polysaccharides whose properties make it an excipient useful in pharmacy and cosmetology.
  • mucilage of Gleditsia particularly G. triacanthos and G. ferox, preferably treated by extrac ⁇ with hot water, has laxative properties when used orally.
  • the subject of the present invention is therefore the use of Gleditsia mucilage, and more particularly of a Gleditsia mucilage extract, as a slimming active ingredient in a topical cosmetic and / or dermatological composition, and a new cosmetic composition and / or or dermatological mucosa-based Gleditsia.
  • compositions of the invention are topical compositions which comprise an effective amount of Gleditsia mucilage.
  • compositions have excellent properties ⁇ summers used in cosmetics and dermatology for skin care, more particularly for preventing and / or treating fat overload and cellulite.
  • the invention can include preparing composi ⁇ tions to improve the bags under the eyes and the oval face, the release may be due to the presence of excess adipose tissue.
  • the present invention also relates to a non-therapeutic cosmetic method for preventing and combating adipose overloads and cellulite, comprising applying to the areas of the skin concerned a topical composition comprising an effective amount of Gleditsia mucilage according to the present invention.
  • the subject of the invention is also a pharmaceutical composition, more particularly a dermatological composition, comprising mucilage of Gleditsia with a lipolytic effect, and at least one carrier and / or excipient for topical application acceptable in dermatology, in particular for the prevention and / or treatment of fat overload and cellulite.
  • the invention finally relates to the cosmetic use of mucilage Gleditsia in a topical composition thinned ⁇ health, as well as its cosmetic use for the prepa ration ⁇ a topical composition for the prevention and treatment of excess adipose and cellulite.
  • compositions according to the present invention are distinguished in that they comprise Gleditsia mucilage in an amount effective to provide a lipolytic effect for the prevention and / or treatment of adipose overloads and cellulitis, especially the bags under the eyes and dark circles, as well as acceptable carriers and excipients in dermatology and cosmetology.
  • the tests carried out showed that the Gleditsia mucilage shows no cytotoxicity, particularly because of the absence of triacanthine.
  • the lipolytic effect evaluation tests were performed using 1% Gleditisia mucilage samples on human adipocytes and keratinocytes in culture.
  • Gleditsia mucilage at 1% increases the level of glycerol liberated significantly, comparable to the effect of caffeine, although lower but without the known side effects of caffeine and without the difficulties of formulation of caffeine-based compositions resulting from its low solubility in water and alcohols.
  • Gleditisa can be used in the present invention, and for example Gleditsia triachhos L. (or Gleditsia ferox), Gleditsia australis Hemsl. (still called Gleditsia will do Merr., Gleditsia sinensis or Gleditsia thorelii), Gleditsia africana Walv. (or Gleditsia africanum Harms.), Gleditsia japonica Micq., Gleditsia javanica Lam. (or Parria javanica Merr.), Gleditsia officialis Hems.
  • Gleditsia inermis Gleditsia amorphoides, Gleditsia aquatica, Gleditsia capsica, Gleditsia delavayi, Gleditsia horrida, Gleditsia koraiensis, Gleditsia macratha, Geditsia rolfei, Gleditsia texana.
  • Gleditsia triacanthos L. Honey locust or Honey locust
  • Mucilage of Gleditsia used in the present inven ⁇ can be obtained from seeds which are treated such as by crushing and extraction in hot water in an acidic medium (sugar acids) or in an alkaline medium and then collected mucilage by precipitation with alcohol. The precipitate is then taken up in water, collected and dried and then mixed if necessary with maltodextrin to prevent caking of the powder.
  • Gleditsia mucilage is a beige-yellow powder of characteristic odor, soluble in water, the analytical characteristics of which are as follows:
  • the Gleditsia extract content of the compositions according to the present invention is generally between 1 and 15%, preferably between 5 and 10%.
  • the plant / extract ratio is generally between 5: 1 and 6: 1.
  • compositions according to the invention may contain, besides the mucilage of Gleditsia, secondary active STRENGTHENING ⁇ cant or advantageously supplementing their activity, and ⁇ compati ble, that is to say, not able to react on each other or hide or limit their respective effects.
  • the secondary active agents may be chosen from a complementary lipolytic agent, a venotonic agent, or from cocoa polyphenols, a mimosa seed extract and a marigold extract that favorably act on the stimulation of neoformed collagens, or else a restructuring agent such as Centella asiatica which has a firming and stimulating effect on the cutaneous microcirculation.
  • the complementary lipolytic agents may be chosen in particular from xanthine bases such as caffeine, theobromine and theophylline, extracts of algae, extracts of ivy, extracts of Coleus, silanols such as monomethylsilanol, chaulmoogra oil, guggulipids, etc.
  • chaulmoogra oil which is extracted from seeds of plants of the genus Hydnocarpus, for example varieties such as Hydnocarpus wightiana and Hydnocarpus anthelmintica, can be advantageously associated with the composition according to the present invention.
  • the algae extract may be selected from Gelidium cartilagineum, Fucus and laminaria such as Laminaria digitata.
  • the Coleus extract may be Coleus forskohlii, which has the property of stimulating adenyl cyclase at the level of the adipocyte, and contributes to the lypolytic action.
  • a complementary active agent useful in the composition of the invention may be chosen from substances with venotonic action such as ruscogenin, escin, hederogenin, Ginkgo biloba and troxerutin. These veinotonics can be used as extracts of saponoside plants, coumarin plants or flavonoid plants.
  • Saponoside plants have significant venotonic activity as well as anti-inflammatory and anti-oedematous properties. They also frequently vasoconstrictor properties promoting capillary circulation as well as improving circulated decongestant lymphatic ⁇ tion. These plants may be selected from the bunt (Ruscus aculeatus) from which ruscogenin, the ivy which provides hederagenin, and the horse chestnut (Aesculus hippocastanum) from which the escin is extracted are extracted.
  • bunt Ruscus aculeatus
  • ivy which provides hederagenin
  • horse chestnut Aesculus hippocastanum
  • Plants provide a coumarin anti-Oede share ⁇ Spying, vascular-protective and venotonic, and may be chosen from horse chestnut which escu- loside extracted, and melilot (Melilotus officinalis), which was extracted melilotoside which hydrolyzes to coumarin.
  • Flavonoids have the effect of reducing capillary fragility and strengthening the resistance of the vessels.
  • ginkgo Ginkgo biloba
  • Sophora japonica from which troxerutin can be extracted
  • the composition according to the invention may comprise, for example, between 1 and 15% Gleditsia mucilage and, where appropriate, between 0.05 and 1% by weight of veinotonic with respect to the total weight of the composition. According to a preferred-competitive, these concentrations between 5 and 10% mucilage of Gleditsia and between 0.1 and 0.5% by weight of venotonic agent relative to the total weight of the compo sition ⁇ .
  • each component in the composition may be made according to the utili zation ⁇ envisaged.
  • lower doses in the form of milk or cream dosed at approximately 1 to 10% in mucilage of Gleditsia, are preferably used, whereas a spot treatment may require higher doses, for example a gel. dosed between 10 and 15%.
  • topical compositions can be used advantageously in dermatology and cosmetology for the treatment or prevention of fat overload and cellulite.
  • the Gleditsia mucilage-based composition according to the present invention supplemented if necessary by substances with complementary activity, as indicated above, used under normal conditions of use for 30 to 90 consecutive days, to treat fat overloads. or cellulite, showed excellent skin tolerance.
  • compositions of the invention make it possible in particular to improve the oval of the face, the relaxation of which may be due to the presence of fat overloads. They have proven particularly useful in the treatment of the eye area, for the reduction of fat pockets and dark circles under the eyes.
  • compositions according to the present invention may be presented in the galenical forms conventionally used for topical application, that is to say in the form of a concentrated lotion, gel, emulsion (in particular cream or milk), balm, mask , ointment, nanocapsules, or liposomes, containing compatible and pharmaceutically acceptable excipients and common carriers. They are preferably used in the form of creams, gels and balms.
  • Topical administration are prepared by the usual techniques, and for example, in the case of a cream, by dispersion of a fatty phase in an aqueous phase to obtain an oil-in-water emulsion, or conversely to prepare a water-in-oil emulsion.
  • creams it is preferred to use lamellar structure emulsions containing little or no ethoxylated products.
  • an aqueous extract preferably a hydroglycolic extract.
  • the topical compositions according to the invention may comprise excipients suitable for external topical administration, in particular dermatologically and cosmetologically acceptable excipients.
  • excipients suitable for formulation are well known to those skilled in the art and include in particular penetrating agents such as ethoxydiglycol, phytantriol, octyl dodecanol and escin; thickeners such as natural gums and synthetic polymers; emollients and surfactants such as cetearyl octanoate, isopropyl myristate, cetearyl isononanoate, dimethicone, cyclomethicone, polyglyceryl 3-diisostearate, hydrogenated polyisobutene, cetyl alcohol, cetyl palmitate cetyl phosphate; emulsifiers such as polyglycerol derivatives; conservatives such as the phenoxyethanol, methyl parahydroxybenzoate (methylparaben), ethyl parahydroxybenzo
  • moisturizing agents such as propylene glycol, glycerin, butylene glycol, sodium salt of pyrrolidone carboxylic acid (PCA sodium), and also antioxidant vitamins such as vitamin E, for example tocopherol acetate or tocotrienol, vitamin C, natural polyphenols.
  • PCA sodium pyrrolidone carboxylic acid
  • antioxidant vitamins such as vitamin E, for example tocopherol acetate or tocotrienol, vitamin C, natural polyphenols.
  • an eye-contour gel having the following weight composition is prepared.
  • the gel having the composition indicated above can be used in local application, once or twice a day for 5 to 10 weeks.
  • the first effects are observed at the 3rd week.
  • the treatment can be prolonged without limitation in time.
  • an eye contour having the following weight composition is prepared.
  • the balm having the composition indicated above is used in application to the areas to be treated, once a day for a period which may be from 1 to 3 months.
  • Gleditsia mucilage according to the present invention on lipolysis was verified by tests for evaluating the lipolytic effect by releasing glycerol in a culture medium of human adipocytes. This activity is indeed significant of a lipolytic effect resulting in a hydrolysis of total lipids in glycerol and free fatty acids.
  • the cultured human adipocytes prepared as indicated below are used.
  • the adipocytes are prepared from samples of human adipose tissue from plastic surgery operations.
  • the tissues are cut out and incubated at 37 ° C. for 40 to 60 minutes with shaking, in a type II collagenase solution (1 mg / ml in HBSS buffer at pH 7.4) at a rate of 4 volumes. solution for 1 volume of tissue.
  • the cells are recovered by filtration (nylon filter 250 ⁇ m).
  • the adipocytes thus isolated are separated by flotation and the adipocyte suspension is washed three times with a KBR buffer to remove any trace of collagenase.
  • composition of the KBR buffer is as follows (for 1 liter):
  • Gleditsia mucilage application set 1% 0.2%
  • the enzymatic determination of glycerol consists in measuring the oxidation of the reduced form of nicotinamide adenine dinucleotide (NADH) by measurement. optical density (OD) at 385 nm. Indeed, the amount of oxidized NADH during the Glycerol conversion reaction to pyruvate and then lactate is proportional to the total concentration of glycerol.
  • Glycerol reacts under the action of three enzymes (glycerokinase, pyruvate kinase and lactate dehydrokinase) as follows:
  • ADP reacts with phosphoenolpyruvate to release pyruvate and ATP;
  • a glycilglycine buffer (pH 7.4) containing NADH (0.83 mg), ATP (2 mg), magnesium sulfate (1 mg) and phosphoenolpyruvate (1 mg) is used.
  • the enzyme suspension consists of pyruvate kinase (240 ⁇ ) and lactate dehydrogenase (220 ⁇ ). Glycerokinase (34 ⁇ ) is used in suspension.
  • the method consists in mixing all the elements of reactions 2) and 3) above, in the presence and in the absence of adipocyte culture media (with and without the product to be tested), and measuring the DO (Ai), and in a second step to start the reaction 1) adding glycerokinase.
  • the resulting OD is then measured at 385 nm (A 2 ).
  • the difference in OD is obtained from the differences in OD for the product to be tested on the one hand, and for the control on the other hand.

Abstract

The invention relates to a composition that can be used in dermatology and/or cosmetics. The composition includes a sufficient amount of Gleditsia mucilage optionally combined with a venotonic agent. The invention can be used in cosmetic or dermatological compositions for treating excess fat and cellulite.

Description

COMPOSITION A BASE DE GLEDITSIA POUR LE TRAITEMENT DES  GLEDITSIA-BASED COMPOSITION FOR THE TREATMENT OF
SURCHARGES ADIPEUSES .  ADDITIONAL SURCHARGES.
La présente invention concerne une nouvelle composition cosmétique et/ou dermatologique à propriété lipolytique, et plus particulièrement une composition à base de mucilage de Gleditsia destinée à traiter et/ou à prévenir les surcharges adipeuses et la cellulite. The present invention relates to a novel cosmetic and / or dermatological composition with lipolytic property, and more particularly to a composition based on Gleditsia mucilage intended to treat and / or prevent fat overload and cellulite.
La peau constitue un véritable organe comprenant plusieurs couches intégrées, allant de la couche super¬ ficielle, l'épiderme, jusqu'aux couches plus profondes, le derme et l'hypoderme, et chacune possède des propriétés spéci- fiques permettant à l'ensemble de réagir et de s'adapter aux conditions de son environnement. The skin is a real organ comprising a plurality of integrated layers, from super ficial ¬ layer, the epidermis, to the deeper layers, the dermis and the hypodermis, and each has spe- cific properties allowing all to react and adapt to the conditions of its environment.
L'épiderme, principalement composé de kératinocytes (90% des cellules épidermiques ) , de mélanocytes (2 à 3% des cellules épidermiques) et des cellules de Langerhans, a une épaisseur variable selon les différentes parties du corps. Etant donné qu'il constitue la couche externe de la peau, l'épiderme joue un rôle fondamental pour assurer la protection et le maintien d'une bonne trophicité. C'est pourquoi de nombreuses compositions ont été mises au point afin de le protéger et d'améliorer ses fonctions, et notamment de renforcer son élasticité et sa fermeté.  The epidermis, composed mainly of keratinocytes (90% of epidermal cells), melanocytes (2 to 3% of epidermal cells) and Langerhans cells, has a variable thickness depending on the different parts of the body. Since it constitutes the outer layer of the skin, the epidermis plays a fundamental role in ensuring the protection and maintenance of good trophicity. This is why many compositions have been developed to protect and improve its functions, including strengthening its elasticity and firmness.
Le derme, plus épais, solide, riche en nerfs, en vaisseaux sanguins et en glandes sudoripares, se compose principalement de collagène, d'élastine et de protéoglycanes . Ces trois types de molécules sont synthétisés par les fibroblastes dermiques. Les fibres de collagène, qui représen¬ tent 70% du poids sec du derme, assurent la résistance mécanique et la texture de la peau, l'élastine est responsable de l'élasticité, et les protéoglycanes jouent un rôle majeur de structure et d'hydratation de la peau. D'autres cellules comme les macrophages et les leucocytes sont également présentes dans la couche du derme. The dermis, thicker, solid, rich in nerves, blood vessels and sweat glands, consists mainly of collagen, elastin and proteoglycans. These three types of molecules are synthesized by dermal fibroblasts. Collagen fibers, which repre ¬ tent 70% of the dry weight of the dermis, ensure the mechanical strength and texture of the skin, elastin is responsible for the elasticity, and proteoglycans play a major role structure and hydration of the skin. Other cells such as macrophages and leucocytes are also present in the dermis layer.
B10060 O L'hypoderme, qui est la couche la plus profonde de la peau, contient les adipocytes qui produisent des lipides pour que le tissu sous-cutané fabrique une couche grasse protégeant les muscles, les os et les organes internes contre les chocs. B10060 O The hypodermis, which is the deepest layer of skin, contains lipid-producing fat cells so that the subcutaneous tissue makes a fat layer that protects muscles, bones, and internal organs from shock.
Les adipocytes synthétisent des triglycérides par lipo- génèse à partir d'acides gras libres et de glycérol provenant de la dégradation du glucose. Les acides gras et le glucose sont apportés à l'organisme par les aliments. Inversement, les triglycérides contenus dans les adipocytes subissent une lipolyse sous l'action d'enzymes et libèrent du glycérol ou des esters de glycérol ainsi que des acides gras qui peuvent à leur tour circuler dans l'organisme et/ou être captés par des adipocytes où ils sont à nouveau transformés en triglycérides par lipogénèse. Ainsi, en cas de déséquilibre entre la lipogénèse et la lipolyse, il peut se produire une accumu¬ lation excessive de triglycérides qui se traduit par des surcharges adipeuses, ou surcharges graisseuses localisées. Adipocytes synthesize triglycerides by lipogenesis from free fatty acids and glycerol from glucose degradation. Fatty acids and glucose are brought to the body by food. Conversely, the triglycerides contained in adipocytes undergo lipolysis by the action of enzymes and release glycerol or glycerol esters as well as fatty acids which can in turn circulate in the body and / or be captured by adipocytes. where they are again transformed into triglycerides by lipogenesis. Thus, in case of imbalance between lipogenesis and lipolysis, it can produce excessive accumu ¬ lation triglycerides which results in excess adipose, or fat deposits localized.
Les surcharges adipeuses sont des défauts susceptibles de nuire à l'aspect esthétique de l'individu, et elles consti- tuent aussi des états physiologiques anormaux chez l'homme, mais surtout chez la femme, où les accumulations de cellulite sont toujours jugées disgracieuses. Ces surcharges adipeuses peuvent aussi se traduire par des poches sous les yeux et des cernes. Ces états pathologiques, bien que différents de l'obésité, nécessitent généralement un traitement systémique. Bien souvent, à défaut de traitement thérapeutique, un traitement cosmétique est souhaité pour lutter contre les surcharges adipeuses, et pour en atténuer les effets disgracieux .  Adipose overloads are defects that can affect the aesthetic appearance of the individual, and they also constitute abnormal physiological states in humans, but especially in women, where accumulations of cellulite are still considered unsightly. These fat overloads can also result in bags under the eyes and dark circles. These conditions, although different from obesity, usually require systemic treatment. Often, in the absence of therapeutic treatment, a cosmetic treatment is desired to fight against fat overload, and to mitigate the unsightly effects.
De nombreuses substances, notamment d'origine végétale, ont été proposées pour tenter de lutter contre la cellulite et les surcharges adipeuses, et diverses compositions ont été mises au point. Ainsi, des oligomères procyanidoliques dérivés des pépins de raisin, des flavonoïdes, tel que le ruscus, les extraits de vigne rouge, de marron d'inde, d'hamamélis, ont une certaine action de drainage circulatoire. La caféine, et divers dérivés de la caféine, peuvent contribuer à diminuer l'œdème et la rétention d'eau, à augmenter la lipolyse et à limiter le stockage des graisses. Toutefois, la caféine à concentration élevée peut entraîner des effets secondaires, par exemple des palpitations, chez certains sujets. De plus, sa faible solubilité dans l'eau et les alcools est un inconvénient pour la formulation de compo¬ sitions cosmétiques. C'est pourquoi des dérivés ou des associations à base de caféine ont été proposés, et par exemple des caféine carboxylates comme dans le brevet FR 2 639 541 et l'association de caféine et d'extraits d'algues comme dans le brevet FR 2 490 492. La demande de brevet WO 2006045932 propose d'utiliser de l'huile de chaulmoogra, éventuellement en association avec une base xanthique telle que la caféine, en raison de son effet lipo- lytique vérifié par son action sur les adipocytes humains en culture . Many substances, especially of plant origin, have been proposed to try to fight against cellulite and fat overload, and various compositions have been developed. Thus, procyanidolic oligomers derived from grape seeds, flavonoids, such as ruscus, red vine extracts, horse chestnut, witch hazel, have a certain circulatory drainage action. Caffeine, and various caffeine derivatives, can help reduce edema and fluid retention, increase lipolysis, and limit fat storage. However, high concentration caffeine may cause side effects, such as palpitations, in some subjects. In addition, its low solubility in water and alcohols is a disadvantage for the formulation of cosmetic compo ¬ sions. This is why derivatives or combinations based on caffeine have been proposed, and for example caffeine carboxylates as in FR 2,639,541 and the combination of caffeine and algae extracts as in FR 2 490 492. The patent application WO 2006045932 proposes to use chaulmoogra oil, optionally in combination with a xanthine base such as caffeine, because of its lipolytic effect verified by its action on human adipocytes in culture. .
Le Gleditsia, plus particulièrement l'espèce G. triacanthos, est un arbre de 20 à 30 m de hauteur faisant partie de la famille des Fabacées, originaire d'Amérique du Nord. Ses rameaux sont garnis d'épines simples ou ramifiées, ses feuilles, de couleur verte brillante tournant au jaune à l'automne, sont caduques, doublement composées de folioles bordées de dents arrondies. Le fruit du Gleditsia est une gousse longue, aplatie en forme de faux et contenant de 10 à 20 graines, se desséchant sur l'arbre avant de tomber.  Gleditsia, more specifically the species G. triacanthos, is a tree 20 to 30 m tall belonging to the family Fabaceae, native to North America. Its branches are adorned with simple or branched spines, its leaves, brilliant green in color turning yellow in autumn, are deciduous, doubly composed of leaflets bordered with rounded teeth. The fruit of Gleditsia is a long, flattened pod in the shape of a scythe and containing from 10 to 20 seeds, drying on the tree before falling.
Le genre Gleditsia regroupe de nombreuses espèces et variétés existant dans le monde. On peut citer les espèces suivantes : Gleditsia triacanthos L. (ou Gleditsia ferox) , Gleditsia australis Hemsl. (encore appelé Gleditsia fera Merr . , Gleditsia sinensis ou Gleditsia thorelii) , Gleditsia africana Walv. (ou Gleditsia africanum Harms . ) , Gleditsia japonica Micq., Gleditsia javanica Lam. (ou Parria javanica Merr.), Gleditsia officinalis Hemsl., Gleditsia inermis, Gleditsia amorphoides, Gleditsia aquatica, Gleditsia capsica, Gleditsia delavayi, Gleditsia horrida, Gleditsia koraiensis, Gleditsia macracantha, Geditsia rolfei, Gleditsia texana. The genus Gleditsia includes many species and varieties existing in the world. The following species may be mentioned: Gleditsia triacanthos L. (or Gleditsia ferox), Gleditsia australis Hemsl. (still called Gleditsia will do Merr., Gleditsia sinensis or Gleditsia thorelii), Gleditsia africana Walv. (or Gleditsia africanum Harms.), Gleditsia japonica Micq., Gleditsia javanica Lam. (or Parria javanica Merr.), Gleditsia officinalis Hemsl., Gleditsia inermis, Gleditsia amorphoides, Gleditsia aquatica, Gleditsia capsica, Gleditsia delavayi, Gleditsia horrida, Gleditsia koraiensis, Gleditsia macracantha, Geditsia rolfei, Gleditsia texana.
Dans la pharmacopée africaine, la pulpe de fruit est utilisée pour traiter certaines maladies pulmonaires. Son utilisation pour le traitement du rhume, de la dyspepsie, de la rougeole, de la coqueluche et de certains troubles sanguins a également été rapportée. R.K. Rakhmanberdyeva et al., Médicinal and Aromatic Plants Abstracts, vol. 25 n° 1 (Fev. 2003) ont montré que les graines de Gleditsia triacanthos contiennent des galactomannanes , et Y. Yamamoto et al., Bioscience Biotechnology and Biochemistry, vol. 64 n° 10, p. 2165-2171 (oct. 2000) ont montré que des mélanges de galacto- mannanne et de gomme xanthane peuvent avoir un effet hypo- lipidémique chez le rat.  In the African pharmacopoeia, fruit pulp is used to treat certain lung diseases. Its use for the treatment of colds, dyspepsia, measles, whooping cough and certain blood disorders has also been reported. R.K. Rakhmanberdyeva et al., Medicinal and Aromatic Plants Abstracts, vol. No. 1 (Feb. 2003) showed that the seeds of Gleditsia triacanthos contain galactomannans, and Y. Yamamoto et al., Bioscience Biotechnology and Biochemistry, vol. 64 No. 10, p. 2165-2171 (Oct. 2000) have shown that mixtures of galactomannan and xanthan gum can have a hypolipidemic effect in the rat.
Les Gleditsia contiennent diverses substances utiles, notamment de la triacanthine que l'on trouve principalement dans les gousses et les feuilles, qui peuvent contenir environ 100 mg/kg de triacanthine par kg de plante sèche.  Gleditsia contain a variety of useful substances, including triacanthine, which is found mainly in pods and leaves, which may contain about 100 mg / kg of triacanthine per kg of dry plant.
La triacanthine est un alcaloïde à structure dérivée de purine, analogue à celle de la kinétine, dont les propriétés ont été décrites par Beauchesne et al., Physiologia Plantarum, vol. 16 (1963) . Il a été montré qu'elle présente une activité hypotensive, cardiotonique et antispasmodique, avec une toxicité peu élevée, puisque sa DL50 est de l'ordre de 30 mg/kg, inférieure à celle de la caféine. Son action cardiotonique chez l'animal a été décrite par 0. Foussard- Blanpin et al., Annales Pharmaceutiques Françaises vol. 27, p. 257-259 (1969) . La demande de brevet WO 2008009813 décrit une composition comprenant un extrait de Gleditsia et de la triacanthine présentant un effet lipolytique utile pour le traitement des surcharges adipeuses et de la cellulite.  Triacanthine is a purine-derived alkaloid, analogous to that of kinetin, whose properties have been described by Beauchesne et al., Physiologia Plantarum, vol. 16 (1963). It has been shown to have hypotensive, cardiotonic and antispasmodic activity, with low toxicity, since its LD50 is of the order of 30 mg / kg, lower than that of caffeine. Its cardiotonic action in animals has been described by 0. Foussard-Blanpin et al., French Pharmaceutical Annals vol. 27, p. 257-259 (1969). The patent application WO 2008009813 describes a composition comprising a Gleditsia extract and triacanthine having a lipolytic effect useful for the treatment of fat overload and cellulite.
Par contre, les graines et le mucilage de Gleditsia ne contiennent pratiquement pas de triacanthine. Diverses parties de la plante contiennent aussi des flavonoïdes, des saponines (dérivés de catéchine) , et le mucilage des graines est princi¬ palement riche en arabinose. Le mucilage de Gleditsia peut être obtenu par traitement des graines, par exemple par extraction aqueuse en milieu acide, séchage et mélange à de la maltodextrine pour éviter le mottage de la poudre. Le produit sec obtenu a généralement une teneur importante en polysaccharides . On the other hand, Gleditsia seeds and mucilage contain practically no triacanthine. Various parts of the plant also contain flavonoids, saponins (derived from catechin), and the seed mucilage is princi ¬ palely rich in arabinose. Gleditsia mucilage can be obtained by treatment of the seeds, for example by aqueous extraction in an acid medium, drying and mixing with maltodextrin to prevent caking of the powder. The dry product obtained generally has a high content of polysaccharides.
Le brevet FR 1602259 décrit l'utilisation d'un extrait aqueux de mucilage de graines de Gleditsia triacanthos, traité pour obtenir une solution de polyosides dont les propriétés en font un excipient utile en pharmacie et en cosmétologie. Selon le brevet GB 950997, le mucilage de Gleditsia, en particulier G. triacanthos et G. ferox, traité de préférence par extrac¬ tion à l'eau chaude, a des propriétés laxatives lorsqu'il est utilisé par voie orale. The patent FR 1602259 describes the use of an aqueous mucilage extract of Gleditsia triacanthos seeds, treated to obtain a solution of polysaccharides whose properties make it an excipient useful in pharmacy and cosmetology. According to GB 950 997, mucilage of Gleditsia, particularly G. triacanthos and G. ferox, preferably treated by extrac ¬ with hot water, has laxative properties when used orally.
Bien que de nombreuses compositions dermatologiques et cosmétiques aient été proposées, il existe toujours un besoin de pouvoir disposer de nouvelles compositions topiques alter¬ natives permettant de lutter contre les surcharges adipeuses et la cellulite, et plus particulièrement des compositions topiques à base d'extraits végétaux appropriés provenant de plantes connues pour leurs propriétés favorables à une telle activité . Although many dermatological and cosmetic compositions have been proposed, there is still a need to be able to have new topical compositions alter ¬ natives to fight against fat overload and cellulite, and more particularly topical compositions based on plant extracts from plants known for their favorable properties for such activity.
Les études effectuées par la demanderesse ont montré que le mucilage de Gleditsia procure des effets inattendus utiles dans le traitement et la prévention des surcharges adipeuses et de la cellulite.  The studies carried out by the Applicant have shown that the mucilage of Gleditsia provides unexpected effects useful in the treatment and prevention of fat overload and cellulite.
La présente invention a donc pour objet l'utilisation du mucilage de Gleditsia, et plus particulièremetn d'un extrait de mucilage de Gleditsia, à titre d'actif amincissant dans une composition cosmétique et/ou dermatologique topique, et une nouvelle composition cosmétique et/ou dermatologique à base de mucilage de Gleditsia.  The subject of the present invention is therefore the use of Gleditsia mucilage, and more particularly of a Gleditsia mucilage extract, as a slimming active ingredient in a topical cosmetic and / or dermatological composition, and a new cosmetic composition and / or or dermatological mucosa-based Gleditsia.
Les compositions de l'invention sont des compositions topiques qui comprennent une quantité efficace de mucilage de Gleditsia .  The compositions of the invention are topical compositions which comprise an effective amount of Gleditsia mucilage.
De telles compositions présentent d'excellentes propri¬ étés utilisables en cosmétique et en dermatologie pour les soins de la peau, plus particulièrement pour prévenir et/ou traiter les surcharges adipeuses et la cellulite. Such compositions have excellent properties ¬ summers used in cosmetics and dermatology for skin care, more particularly for preventing and / or treating fat overload and cellulite.
L' invention permet notamment la préparation de composi¬ tions destinées à améliorer les poches sous les yeux et l'ovale du visage, dont le relâchement peut être dû à la présence de surcharges adipeuses. The invention can include preparing composi ¬ tions to improve the bags under the eyes and the oval face, the release may be due to the presence of excess adipose tissue.
La présente invention a encore pour objet un procédé cosmétique non thérapeutique pour prévenir et combattre les surcharges adipeuses et la cellulite, consistant à appliquer sur les zones de la peau concernées une composition topique comprenant une quantité efficace de mucilage de Gleditsia selon la présente invention.  The present invention also relates to a non-therapeutic cosmetic method for preventing and combating adipose overloads and cellulite, comprising applying to the areas of the skin concerned a topical composition comprising an effective amount of Gleditsia mucilage according to the present invention.
L'invention a également pour objet une composition pharmaceutique, plus particulièrement dermatologique, comprenant du mucilage de Gleditsia à effet lipolytique, et au moins un support et/ou excipient pour application topique acceptable en dermatologie, notamment pour la prévention et/ou le traitement des surcharges adipeuses et de la cellulite.  The subject of the invention is also a pharmaceutical composition, more particularly a dermatological composition, comprising mucilage of Gleditsia with a lipolytic effect, and at least one carrier and / or excipient for topical application acceptable in dermatology, in particular for the prevention and / or treatment of fat overload and cellulite.
L'invention a enfin pour objet l'utilisation cosmétique du mucilage de Gleditsia dans une composition topique amincis¬ sante, ainsi que son utilisation cosmétique pour la prépa¬ ration d'une composition topique destinée à la prévention et au traitement des surcharges adipeuses et de la cellulite. The invention finally relates to the cosmetic use of mucilage Gleditsia in a topical composition thinned ¬ health, as well as its cosmetic use for the prepa ration ¬ a topical composition for the prevention and treatment of excess adipose and cellulite.
Les compositions suivant la présente invention se distin- guent en ce qu'elles comprennent du mucilage de Gleditsia en une quantité efficace pour procurer un effet lipolytique permettant la prévention et/ou le traitement des surcharges adipeuses et de la cellulite, notamment les poches sous les yeux et les cernes, ainsi que des supports et excipients acceptables en dermatologie et en cosmétologie.  The compositions according to the present invention are distinguished in that they comprise Gleditsia mucilage in an amount effective to provide a lipolytic effect for the prevention and / or treatment of adipose overloads and cellulitis, especially the bags under the eyes and dark circles, as well as acceptable carriers and excipients in dermatology and cosmetology.
Ainsi, les études réalisées par la demanderesse ont démontré de manière inattendue que le mucilage de Gleditsia présente un effet lipolytique vérifié par une action sur les adipocytes humains en culture, se traduisant par une nette augmentation du glycérol libéré. Ce résultat est inattendu car le mucilage de Gleditsia, au contraire des gousses et des feuilles, ne contient pas de triacanthine dont l'effet lipolytique est connu. Thus, the studies carried out by the Applicant have unexpectedly demonstrated that mucilage of Gleditsia has a lipolytic effect verified by an action on human adipocytes in culture, resulting in a clear increase in glycerol released. This result is unexpected because Gleditsia mucilage, unlike pods and leaves, does not contain triacanthine, the lipolytic effect of which is known.
De plus, aux doses utilisées, les essais effectués ont montré que le mucilage de Gleditsia ne présente aucune cytotoxicité en raison notamment de l'absence de triacanthine.  In addition, at the doses used, the tests carried out showed that the Gleditsia mucilage shows no cytotoxicity, particularly because of the absence of triacanthine.
Les tests d'évaluation de l'effet lipolytique ont été effectués en utilisant des échantillons de mucilage de Gleditisia dosés à 1%, sur des adipocytes et des kératinocytes humains en culture.  The lipolytic effect evaluation tests were performed using 1% Gleditisia mucilage samples on human adipocytes and keratinocytes in culture.
Les résultats des tests in vitro détaillés ci-après, ont mis en évidence l'effet lipolytique significatif sans effet secondaire néfaste.  The results of the in vitro tests detailed below have shown the significant lipolytic effect without any harmful side effects.
Ainsi, on a constaté que le mucilage de Gleditsia à 1% augmente le taux de glycérol libéré de manière significative, comparable à l'effet de la caféine, bien que plus faible mais sans les effets secondaires connus de la caféine et sans les difficultés de formulation de compositions à base de caféine résultant de sa faible solubilité dans l'eau et les alcools.  Thus, it was found that Gleditsia mucilage at 1% increases the level of glycerol liberated significantly, comparable to the effect of caffeine, although lower but without the known side effects of caffeine and without the difficulties of formulation of caffeine-based compositions resulting from its low solubility in water and alcohols.
Les résultats sont explicités dans les exemples ci-après. Plusieurs espèces de Gleditisa peuvent être utilisées dans la présente invention, et par exemple Gleditsia tria- canthos L. (ou Gleditsia ferox) , Gleditsia australis Hemsl. (encore appelé Gleditsia fera Merr . , Gleditsia sinensis ou Gleditsia thorelii) , Gleditsia africana Walv. (ou Gleditsia africanum Harms . ) , Gleditsia japonica Micq., Gleditsia javanica Lam. (ou Parria javanica Merr.), Gleditsia offici- nalis Hems . , Gleditsia inermis, Gleditsia amorphoides, Gleditsia aquatica, Gleditsia capsica, Gleditsia delavayi, Gleditsia horrida, Gleditsia koraiensis, Gleditsia macra- cantha, Geditsia rolfei, Gleditsia texana.  The results are explained in the examples below. Several species of Gleditisa can be used in the present invention, and for example Gleditsia triachhos L. (or Gleditsia ferox), Gleditsia australis Hemsl. (still called Gleditsia will do Merr., Gleditsia sinensis or Gleditsia thorelii), Gleditsia africana Walv. (or Gleditsia africanum Harms.), Gleditsia japonica Micq., Gleditsia javanica Lam. (or Parria javanica Merr.), Gleditsia officialis Hems. , Gleditsia inermis, Gleditsia amorphoides, Gleditsia aquatica, Gleditsia capsica, Gleditsia delavayi, Gleditsia horrida, Gleditsia koraiensis, Gleditsia macratha, Geditsia rolfei, Gleditsia texana.
Parmi ces différentes espèces de Gleditsia, l'espèce Gleditsia triacanthos L. (févier épineux ou févier d'Amérique) est préférée, car elle est facile d'accès et le ramassage de ses gousses d'où sont extraites les graines et le mucilage peut être effectué sans difficulté. Le mucilage de Gleditsia utilisé dans la présente inven¬ tion peut être obtenu à partir des graines que l'on traite par exemple par broyage et extraction à l'eau chaude en milieu acide (sucres acides) ou en milieu alcalin et on recueille ensuite le mucilage par précipitation à l'alcool. Le précipité est ensuite repris à l'eau, recueilli et séché puis mélangé si nécessaire à de la maltodextrine pour éviter le mottage de la poudre . Among these different species of Gleditsia, the species Gleditsia triacanthos L. (Honey locust or Honey locust) is preferred because it is easy to access and the collection of its pods from which are extracted seeds and mucilage can to be carried out without difficulty. Mucilage of Gleditsia used in the present inven ¬ can be obtained from seeds which are treated such as by crushing and extraction in hot water in an acidic medium (sugar acids) or in an alkaline medium and then collected mucilage by precipitation with alcohol. The precipitate is then taken up in water, collected and dried and then mixed if necessary with maltodextrin to prevent caking of the powder.
Sous forme d'extrait sec, le mucilage de Gleditsia se présente en poudre de couleur beige - jaune d'odeur caractéristique, soluble dans l'eau, dont les caractéristiques analytiques sont les suivantes :  In the form of a dry extract, Gleditsia mucilage is a beige-yellow powder of characteristic odor, soluble in water, the analytical characteristics of which are as follows:
- pH : 2,0 - 5,0  - pH: 2.0 - 5.0
- taux d'humidité : < 10,0  - moisture content: <10.0
- polysaccharides : 65%  - polysaccharides: 65%
La teneur en extrait de Gleditsia des compositions suivant la présente invention est généralement comprise entre 1 et 15%, de préférence entre 5 et 10%. Le rapport plante / extrait est généralement compris entre 5:1 et 6:1.  The Gleditsia extract content of the compositions according to the present invention is generally between 1 and 15%, preferably between 5 and 10%. The plant / extract ratio is generally between 5: 1 and 6: 1.
Les compositions selon l'invention peuvent contenir, outre le mucilage de Gleditsia, des actifs secondaires renfor¬ çant ou complétant avantageusement leur activité, et compati¬ bles, c'est-à-dire non susceptibles de réagir les uns sur les autres ou de masquer ou limiter leurs effets respectifs. The compositions according to the invention may contain, besides the mucilage of Gleditsia, secondary active STRENGTHENING ¬ cant or advantageously supplementing their activity, and ¬ compati ble, that is to say, not able to react on each other or hide or limit their respective effects.
Plus particulièrement, les actifs secondaires peuvent être choisis parmi un agent lipolytique complémentaire, un agent veinotonique, ou parmi des polyphénols de cacao, un extrait de graines de mimosa et un extrait de graines de souci agissant favorablement sur la stimulation des collagènes néoformés, ou encore un agent restructurant tel que Centella asiatica qui a un effet raffermissant et stimulant de la microcirculation cutanée.  More particularly, the secondary active agents may be chosen from a complementary lipolytic agent, a venotonic agent, or from cocoa polyphenols, a mimosa seed extract and a marigold extract that favorably act on the stimulation of neoformed collagens, or else a restructuring agent such as Centella asiatica which has a firming and stimulating effect on the cutaneous microcirculation.
Les agents lipolytiques complémentaires peuvent être choisis notamment parmi les bases xanthiques telles que la caféine, la théobromine et la théophylline, des extraits d'algues, des extraits de lierre, des extraits de Coleus, des silanols tel que le monométhylsilanol , l'huile de chaulmoogra, des guggulipides , etc. Ainsi, l'huile de chaulmoogra, qui est extraite de graines de plantes du genre Hydnocarpus, par exemple des variétés telles que Hydnocarpus wightiana et Hydnocarpus anthelmintica, peut être avantageusement associée à la composition suivant la présente invention. L'extrait d'algue peut être choisi parmi Gelidium cartilagineum, des Fucus et des laminaires tels que Laminaria digitata. L'extrait de Coleus peut être le Coleus forskohlii, qui a la propriété de stimuler 1 ' adényl cyclase au niveau de l'adipocyte, et contribue à l'action lypolytique. The complementary lipolytic agents may be chosen in particular from xanthine bases such as caffeine, theobromine and theophylline, extracts of algae, extracts of ivy, extracts of Coleus, silanols such as monomethylsilanol, chaulmoogra oil, guggulipids, etc. Thus, chaulmoogra oil, which is extracted from seeds of plants of the genus Hydnocarpus, for example varieties such as Hydnocarpus wightiana and Hydnocarpus anthelmintica, can be advantageously associated with the composition according to the present invention. The algae extract may be selected from Gelidium cartilagineum, Fucus and laminaria such as Laminaria digitata. The Coleus extract may be Coleus forskohlii, which has the property of stimulating adenyl cyclase at the level of the adipocyte, and contributes to the lypolytic action.
Un agent actif complémentaire utile dans la composition de l'invention peut être choisi parmi les substances à action veinotonique telles que la ruscogénine, l'escine, l'hédéra- génine, le Ginkgo biloba et la troxérutine. Ces veinotoniques peuvent être utilisés sous forme d'extraits de plantes à saponosides, de plantes à coumarine ou de plantes à flavo- noïdes .  A complementary active agent useful in the composition of the invention may be chosen from substances with venotonic action such as ruscogenin, escin, hederogenin, Ginkgo biloba and troxerutin. These veinotonics can be used as extracts of saponoside plants, coumarin plants or flavonoid plants.
Les plantes à saponosides ont une activité veinotonique importante ainsi que des propriétés anti-inflammatoires et anti-oedémateuses. Elles ont aussi fréquemment des propriétés vasoconstrictives favorisant la circulation capillaire ainsi que des propriétés décongestionnantes améliorant la circula¬ tion lymphatique. Ces plantes peuvent être choisies parmi le fragon (Ruscus aculeatus) dont on extrait la ruscogénine, le lierre qui fournit 1 ' hédéragénine, et le marronnier d'Inde (Aesculus hippocastanum) dont on extrait l'escine. Saponoside plants have significant venotonic activity as well as anti-inflammatory and anti-oedematous properties. They also frequently vasoconstrictor properties promoting capillary circulation as well as improving circulated decongestant lymphatic ¬ tion. These plants may be selected from the bunt (Ruscus aculeatus) from which ruscogenin, the ivy which provides hederagenin, and the horse chestnut (Aesculus hippocastanum) from which the escin is extracted are extracted.
Les plantes à coumarine procurent une action anti-oedé¬ mateuse, vasculo-protectrice et veinotonique, et peuvent être choisies parmi le marronnier d'Inde dont on extrait l'escu- loside, et le melilot (Melilotus officinalis) , dont on extrait le mélilotoside qui s 'hydrolyse en coumarine. Plants provide a coumarin anti-Oede share ¬ Spying, vascular-protective and venotonic, and may be chosen from horse chestnut which escu- loside extracted, and melilot (Melilotus officinalis), which was extracted melilotoside which hydrolyzes to coumarin.
Les plantes à flavonoïdes ont pour effet de diminuer la fragilité capillaire et de renforcer la résistance des vais- seaux. On peut utiliser par exemple le ginkgo (Ginkgo biloba) et le Sophora japonica dont on peut extraire la troxérutine. La composition selon l'invention peut comprendre par exemple entre 1 et 15% de mucilage de Gleditsia et, le cas échéant, entre 0,05 et 1% en poids de veinotonique par rapport au poids total de la composition. Suivant une forme préfé- rentielle, ces concentrations sont respectivement entre 5 et 10% de mucilage de Gleditsia et entre 0,1 et 0,5% en poids d'agent veinotonique par rapport au poids total de la compo¬ sition. Flavonoids have the effect of reducing capillary fragility and strengthening the resistance of the vessels. For example, ginkgo (Ginkgo biloba) and Sophora japonica from which troxerutin can be extracted can be used. The composition according to the invention may comprise, for example, between 1 and 15% Gleditsia mucilage and, where appropriate, between 0.05 and 1% by weight of veinotonic with respect to the total weight of the composition. According to a preferred-competitive, these concentrations between 5 and 10% mucilage of Gleditsia and between 0.1 and 0.5% by weight of venotonic agent relative to the total weight of the compo sition ¬.
Le choix de la concentration en chacun des composants dans la composition peut être fait en fonction de l'utili¬ sation envisagée. Pour un traitement prolongé, on utilise de préférence des doses plus faibles, sous forme de lait ou de crème dosée à environ 1 à 10% en mucilage de Gleditsia, tandis qu'un traitement ponctuel peut nécessiter des doses plus élevées, par exemple un gel dosé entre 10 et 15%. The choice of the concentration of each component in the composition may be made according to the utili zation ¬ envisaged. For prolonged treatment, lower doses, in the form of milk or cream dosed at approximately 1 to 10% in mucilage of Gleditsia, are preferably used, whereas a spot treatment may require higher doses, for example a gel. dosed between 10 and 15%.
Ainsi, ces compositions topiques peuvent être utilisées avantageusement en dermatologie et en cosmétologie pour le traitement ou la prévention des surcharges adipeuses et de la cellulite .  Thus, these topical compositions can be used advantageously in dermatology and cosmetology for the treatment or prevention of fat overload and cellulite.
La composition à base de mucilage de Gleditsia suivant la présente invention, complétée le cas échéant par des substances à activité complémentaire, comme indiqué ci-dessus, utilisée dans des conditions normales d'emploi pendant 30 à 90 jours consécutifs, pour traiter des surcharges adipeuses ou de la cellulite, a montré une excellente tolérance cutanée.  The Gleditsia mucilage-based composition according to the present invention, supplemented if necessary by substances with complementary activity, as indicated above, used under normal conditions of use for 30 to 90 consecutive days, to treat fat overloads. or cellulite, showed excellent skin tolerance.
Les compositions de l'invention permettent notamment d'améliorer l'ovale du visage, dont le relâchement peut être dû à la présence de surcharges adipeuses. Elles se sont avérées tout particulièrement utiles dans le traitement du contour des yeux, pour la réduction des poches grasses et des cernes sous les yeux.  The compositions of the invention make it possible in particular to improve the oval of the face, the relaxation of which may be due to the presence of fat overloads. They have proven particularly useful in the treatment of the eye area, for the reduction of fat pockets and dark circles under the eyes.
Les essais effectués ont en effet montré que le mucilage de Gleditsia, à la différence d'un extrait obtenu à partir des feuilles ou des graines, non seulement procure un effet lipolytique permettant une diminution des poches grasses sous les yeux, mais aussi une augmentation de l'AMPc qui est favorable à la microcirculation et au drainage. The tests carried out have indeed shown that the Gleditsia mucilage, unlike an extract obtained from the leaves or seeds, not only provides a lipolytic effect allowing a decrease in fat pockets under eyes, but also an increase in cAMP that is favorable to microcirculation and drainage.
Les compositions conformes à la présente invention peuvent être présentées sous les formes galéniques classi- quement utilisées pour une application topique, c'est-à-dire sous forme de lotion concentrée, gel, émulsion (en particulier crème ou lait) , baume, masque, pommade, nanocapsules , ou liposomes, contenant des excipients et supports usuels compatibles et pharmaceutiquement acceptables. Elles sont utilisées de préférence sous forme de crèmes, gel et baumes.  The compositions according to the present invention may be presented in the galenical forms conventionally used for topical application, that is to say in the form of a concentrated lotion, gel, emulsion (in particular cream or milk), balm, mask , ointment, nanocapsules, or liposomes, containing compatible and pharmaceutically acceptable excipients and common carriers. They are preferably used in the form of creams, gels and balms.
Ces formes d'administration par voie topique sont préparées par les techniques usuelles, et par exemple, dans le cas d'une crème, par dispersion d'une phase grasse dans une phase aqueuse pour obtenir une émulsion huile dans eau, ou inversement pour préparer une émulsion eau dans huile. Dans le cas de crèmes, on préfère utiliser des émulsions à structure lamellaire contenant peu de produits éthoxylés ou n'en contenant pas du tout.  These forms of topical administration are prepared by the usual techniques, and for example, in the case of a cream, by dispersion of a fatty phase in an aqueous phase to obtain an oil-in-water emulsion, or conversely to prepare a water-in-oil emulsion. In the case of creams, it is preferred to use lamellar structure emulsions containing little or no ethoxylated products.
Dans le cas des nanocapsules et des liposomes, il peut être avantageux d'utiliser un extrait aqueux de préférence à un extrait hydroglycolique .  In the case of nanocapsules and liposomes, it may be advantageous to use an aqueous extract, preferably a hydroglycolic extract.
Les compositions topiques selon l'invention peuvent comprendre des excipients appropriés pour une administration topique externe, en particulier des excipients acceptables sur le plan dermatologique et cosmétologique . Ces excipients appropriés pour la formulation sont bien connus de l'homme du métier et comprennent en particulier des agents de pénétration tels que 1 ' éthoxydiglycol , le phytantriol, 1 ' octyl dodécanol et l'escine ; les épaississants tels que les gommes naturelles et les polymères de synthèse ; les émollients et les tensioactifs tels que 1 ' octanoate de cétéaryle, le myristate d ' isopropyle, 1 ' isononanoate de cétéaryle, la diméthicone, la cyclométhicone, le 3-diisostéarate de polyglycéryle, le polyisobutène hydrogéné, l'alcool cétylique, le palmitate cétylique, le phosphate cétylique ; les émulsionnants tels que des dérivés de polyglycérol ; les conservateurs tels que le phénoxyéthanol , le parahydroxybenzoate de méthyle (méthyl- paraben) , le parahydroxybenzoate d'éthyle (éthylparaben) et le Phenonip® associant du phénoxyéthanol et des parahydroxy- benzoates ; les colorants ; les parfums ; etc. The topical compositions according to the invention may comprise excipients suitable for external topical administration, in particular dermatologically and cosmetologically acceptable excipients. Such excipients suitable for formulation are well known to those skilled in the art and include in particular penetrating agents such as ethoxydiglycol, phytantriol, octyl dodecanol and escin; thickeners such as natural gums and synthetic polymers; emollients and surfactants such as cetearyl octanoate, isopropyl myristate, cetearyl isononanoate, dimethicone, cyclomethicone, polyglyceryl 3-diisostearate, hydrogenated polyisobutene, cetyl alcohol, cetyl palmitate cetyl phosphate; emulsifiers such as polyglycerol derivatives; conservatives such as the phenoxyethanol, methyl parahydroxybenzoate (methylparaben), ethyl parahydroxybenzoate (ethylparaben) and Phenonip® associating phenoxyethanol and parahydroxybenzoates; dyes; the perfumes ; etc.
D'autres ingrédients peuvent être utilisés dans les compositions : les agents hydratants tels que le propylène glycol, la glycérine, le butylène glycol, le sel de sodium de l'acide pyrrolidone carboxylique (sodium PCA) , et également les vitamines antioxydantes telles que la vitamine E, par exemple l'acétate de tocophérol ou le tocotriénol, la vitamine C, les polyphénols naturels. On peut également ajouter à la composition des agents de protection contre les rayons ultraviolets, et par exemple des filtres solaires UV-A et UV-B hydrophiles ou lipophiles, ou des pigments formant écran anti¬ ultraviolet, comme par exemple le dioxyde de titane, l'oxyde de zinc, l'oxyde de zirconium ou encore l'oxyde d'aluminium. Other ingredients may be used in the compositions: moisturizing agents such as propylene glycol, glycerin, butylene glycol, sodium salt of pyrrolidone carboxylic acid (PCA sodium), and also antioxidant vitamins such as vitamin E, for example tocopherol acetate or tocotrienol, vitamin C, natural polyphenols. Can also be added to the composition of the protective agents against ultraviolet rays, and for example, UV-A and hydrophilic or lipophilic UV-B, or pigments forming anti ¬ ultraviolet screen, such as titanium dioxide, zinc oxide, zirconium oxide or aluminum oxide.
Les exemples suivants illustrent l'invention plus en détail sans en limiter la portée. Dans tous les exemples de compositions qui suivent, les parties sont exprimées en poids, sauf indication contraire.  The following examples illustrate the invention in more detail without limiting its scope. In all of the following examples of compositions, parts are by weight unless otherwise indicated.
Exemple 1 Example 1
Suivant les techniques classiques, on prépare un gel contour des yeux ayant la composition pondérale suivante.  According to conventional techniques, an eye-contour gel having the following weight composition is prepared.
Eau déminéralisée qsp 100,00  Demineralised water qs 100.00
Polymère carboxyvinylique 0,50  Carboxyvinyl polymer 0.50
Lessive de soude à 10% 0,30  10% sodium hydroxide solution 0.30
Butylène glycol-1,3 4,00  Butylene Glycol-1,3 4.00
Dehydroacétate de sodium 0,05  0.05 Sodium dehydroacetate
Tetrasodium glutamate triacétate 0,10  Tetrasodium glutamate triacetate 0.10
Chlorphénésine 0,20  Chlorphenesin 0.20
Mucilage de Gleditsia 10,00  Mucilage of Gleditsia 10.00
Extrait sec de thé vert 0,20  Dry extract of green tea 0,20
Extrait de Lierre 1,00  Ivy extract 1.00
Eau de Roses 10,00  Rose water 10.00
Eau d'Hamamélis 5,00 Ce gel est préparé suivant les techniques usuelles. Hamamelis water 5.00 This gel is prepared according to the usual techniques.
Le gel ayant la composition indiquée ci-dessus peut être utilisé en application locale, une à deux fois par jour pendant 5 à 10 semaines. Les premiers effets sont observés dès la 3eme semaine. Le traitement peut être prolongé sans limitation dans le temps. The gel having the composition indicated above can be used in local application, once or twice a day for 5 to 10 weeks. The first effects are observed at the 3rd week. The treatment can be prolonged without limitation in time.
Exemple 2 Example 2
Suivant une technique usuelle, on prépare un contour des yeux ayant la composition pondérale suivante.  According to a conventional technique, an eye contour having the following weight composition is prepared.
Eau déminéralisée qsp 100,00  Demineralised water qs 100.00
Tetrasodium glutamate triacétate 0,10  Tetrasodium glutamate triacetate 0.10
1, 3-propanediol 5, 00  1, 3-propanediol 5, 00
Sclerotum Gum et Xanthane Gum 0,20  Sclerotum Gum and Xanthane Gum 0,20
Lécithine hydrogénée 5, 00  Hydrogenated lecithin 5,00
Dehydroacétate de sodium 0,05  0.05 Sodium dehydroacetate
Triglycéride caprique/caprylique 5, 00  Capric / caprylic triglyceride 5 .00
Huile de Jojoba 3, 00  Jojoba Oil 3, 00
Huile de tournesol 3, 00  Sunflower oil 3, 00
Alcool béhénylique 2,00  Behenyl alcohol 2.00
Undécylénate de glycéryle 0,50  Glyceryl undecylenate 0.50
Mucilage de Gleditsia 10,00  Mucilage of Gleditsia 10.00
Extrait de lierre 1,00  Ivy extract 1.00
Extrait sec de thé blanc 0,20  Dry extract of white tea 0,20
Dextran sulfate 0,20  Dextran sulfate 0.20
Eau de Roses 10,00  Rose water 10.00
Eau de Bleuets 20,00  Water of Blueberries 20,00
Le baume ayant la composition indiquée ci-dessus est utilisé en application sur les zones à traiter, une fois par jour pendant une période qui peut être de 1 à 3 mois.  The balm having the composition indicated above is used in application to the areas to be treated, once a day for a period which may be from 1 to 3 months.
Exemple 3 Example 3
L'efficacité du mucilage de Gleditsia suivant la présente invention sur la lipolyse a été vérifiée par des tests d'évaluation de l'effet lipolytique par relargage du glycérol dans un milieu de culture d'adipocytes humains. Cette activité est en effet significative d'un effet lipolytique se traduisant par une hydrolyse des lipides totaux en glycérol et en acides gras libres. The effectiveness of Gleditsia mucilage according to the present invention on lipolysis was verified by tests for evaluating the lipolytic effect by releasing glycerol in a culture medium of human adipocytes. This activity is indeed significant of a lipolytic effect resulting in a hydrolysis of total lipids in glycerol and free fatty acids.
On utilise les adipocytes humains en culture préparés comme indiqué ci-après.  The cultured human adipocytes prepared as indicated below are used.
Les adipocytes sont préparés à partir de prélèvements de tissus adipeux humains provenant d'opérations de chirurgie plastique. Les tissus sont découpés et on les fait incuber à 37°C pendant 40 à 60 minutes sous agitation, dans une solution de collagénase de type II (1 mg/ml dans le tampon HBSS à pH 7,4) à raison de 4 volumes de solution pour 1 volume de tissu .  The adipocytes are prepared from samples of human adipose tissue from plastic surgery operations. The tissues are cut out and incubated at 37 ° C. for 40 to 60 minutes with shaking, in a type II collagenase solution (1 mg / ml in HBSS buffer at pH 7.4) at a rate of 4 volumes. solution for 1 volume of tissue.
Après incubation, les cellules sont récupérées par filtration (filtre nylon 250 ym) . Les adipocytes ainsi isolés sont séparés par flottation et la suspension adipocytaire est lavée trois fois par un tampon KBR pour éliminer toute trace de collagénase.  After incubation, the cells are recovered by filtration (nylon filter 250 μm). The adipocytes thus isolated are separated by flotation and the adipocyte suspension is washed three times with a KBR buffer to remove any trace of collagenase.
La composition du tampon KBR est la suivante (pour 1 litre) :  The composition of the KBR buffer is as follows (for 1 liter):
- NaCl 7, 183 g/1  NaCl 7.13 g / l
- KC1 0,466 g/1  KCl 0.466 g / 1
- CaCl2, 2H20 0, 187 g/1 CaCl 2 , 2H 2 O 0, 187 g / l
- MgS04 0, 144 g/1 MgSO 4 , 144 g / l
- NaH2P04 0, 144 g/1 - NaH 2 P0 4 0, 144 g / 1
- NaH2P03 2, 184 g/1 NaH 2 P0 3 2, 184 g / l
- Glucose 0,826 g/1.  - Glucose 0.826 g / 1.
Pour l'essai on ajoute 3,5% de BSA tampon KBR puis on ajoute le tampon KBRA à pH 7,5.  For the assay, 3.5% BSA buffer KBR is added and KBRA buffer pH 7.5 is added.
On constitue les quatre lots suivants  The following four lots are constituted
Lot témoin négatif ne recevant aucun produit  Negative control lot not receiving any product
Lot témoin positif (application de caféine 0,4%) Lot application de mucilage de Gleditsia 1% 0,2% Le dosage enzymatique du glycérol consiste à doser l'oxydation de la forme réduite du nicotinamide-adénine- dinucléotide (NADH) par mesure de la densité optique (DO) à 385 nm. En effet, la quantité de NADH oxydée au cours de la réaction de conversion du glycérol en pyruvate puis en lactate est proportionnelle à la concentration totale du glycérol. Positive control group (0.4% caffeine application) Gleditsia mucilage application set 1% 0.2% The enzymatic determination of glycerol consists in measuring the oxidation of the reduced form of nicotinamide adenine dinucleotide (NADH) by measurement. optical density (OD) at 385 nm. Indeed, the amount of oxidized NADH during the Glycerol conversion reaction to pyruvate and then lactate is proportional to the total concentration of glycerol.
Le glycérol réagit sous l'action de trois enzymes (glycérokinase, pyruvate kinase et lactate déshydrokinase) de la manière suivante :  Glycerol reacts under the action of three enzymes (glycerokinase, pyruvate kinase and lactate dehydrokinase) as follows:
1) le glycérol réagit avec l'ATP pour donner le glycérol- 3-phosphate et l'ADP ;  1) glycerol reacts with ATP to give glycerol-3-phosphate and ADP;
2) l'ADP réagit avec le phosphoénolpyruvate pour libérer du pyruvate et de l'ATP ;  2) ADP reacts with phosphoenolpyruvate to release pyruvate and ATP;
3) le pyruvate réagit avec la NADH-H- pour procurer le lactate+NAD+ . 3) Pyruvate reacts with NADH-H- to provide lactate + NAD + .
On utilise un tampon glycilglycine (pH 7,4) contenant NADH (0,83 mg) , ATP (2 mg) , sulfate de magnésium (1 mg) et phosphoénolpyruvate (1 mg) . La suspension enzymatique est constituée de pyruvate kinase (240 u) et de lactate déshydro- génase (220 u) . La glycérokinase (34 u) est utilisée en suspension .  A glycilglycine buffer (pH 7.4) containing NADH (0.83 mg), ATP (2 mg), magnesium sulfate (1 mg) and phosphoenolpyruvate (1 mg) is used. The enzyme suspension consists of pyruvate kinase (240 μ) and lactate dehydrogenase (220 μ). Glycerokinase (34 μ) is used in suspension.
La méthode consiste à mélanger dans un premier temps tous les éléments des réactions 2) et 3) ci-dessus, en présence et en l'absence des milieux de culture des adipocytes (avec et sans le produit à tester) , et de mesurer la DO (Ai) , et dans un deuxième temps à démarrer la réaction 1) en ajoutant la glycérokinase .  The method consists in mixing all the elements of reactions 2) and 3) above, in the presence and in the absence of adipocyte culture media (with and without the product to be tested), and measuring the DO (Ai), and in a second step to start the reaction 1) adding glycerokinase.
La DO résultante est alors mesurée à 385 nm (A2) . La différence de DO est obtenue à partir des différences de DO pour le produit à tester d'une part, et pour le témoin d'autre part . The resulting OD is then measured at 385 nm (A 2 ). The difference in OD is obtained from the differences in OD for the product to be tested on the one hand, and for the control on the other hand.
Les résultats obtenus sont regroupés dans le tableau ci- dessous .  The results obtained are summarized in the table below.
glycérol (mg/1) % d' augmentation glycerol (mg / 1)% increase
Témoin négatif 76, 8 ± 6, 1 Negative control 76, 8 ± 6, 1
Témoin positif 100,5 ± 6,2 + 31  Positive control 100.5 ± 6.2 + 31
(caféine 0,4%) (caffeine 0.4%)
Mucilage de Gleditsia 1% 87,1 ± 4,6 + 13 Ces résultats montrent que le traitement des adipocytes humains en culture par le mucilage de Gleditsia suivant l'invention augmente significativement (+13%) le taux de glycérol relargué dans le milieu de culture comparativement à la culture témoin. Mucilage of Gleditsia 1% 87,1 ± 4,6 + 13 These results show that the treatment of human adipocytes in culture by Gleditsia mucilage according to the invention significantly increases (+ 13%) the level of glycerol released into the culture medium compared to the control culture.

Claims

REVENDICATIONS
1. Utilisation du mucilage de Gleditisia comme actif amincissant dans une composition cosmétique et/ou dermato¬ logique topique. 1. Use of mucilage Gleditisia as a slimming active agent in a cosmetic and / or dermato logical ¬ topical.
2. Composition dermatologique, comprenant du mucilage de Gleditsia et au moins un support et/ou excipient pour application topique acceptable en dermatologie.  2. Dermatological composition, comprising Gleditsia mucilage and at least one carrier and / or excipient for topical application acceptable in dermatology.
3. Composition dermatologique, comprenant du mucilage de Gleditsia et au moins un support et/ou excipient pour application topique acceptable en dermatologie, pour le traitement et/ou la prévention des surcharges adipeuses et de la cellulite.  3. Dermatological composition, comprising Gleditsia mucilage and at least one carrier and / or excipient for topical application acceptable in dermatology, for the treatment and / or prevention of fat overload and cellulite.
4. Composition selon la revendication 2 ou 3, caractérisée en ce qu'elle comprend du mucilage de Gleditsia en une quantité efficace pour procurer un effet lipolytique permettant la prévention et/ou le traitement des surcharges adipeuses et de la cellulite, ainsi que des supports et excipients acceptables en dermatologie et en cosmétologie.  4. Composition according to claim 2 or 3, characterized in that it comprises Gleditsia mucilage in an amount effective to provide a lipolytic effect for the prevention and / or treatment of adipose overloads and cellulite, as well as supports and excipients acceptable in dermatology and cosmetology.
5. Composition selon quelconque des revendications 2 à 4, caractérisée en ce que le mucilage de Gleditsia est un mucilage de Gleditsia triacanthos L.  5. Composition according to any one of claims 2 to 4, characterized in that the mucilage of Gleditsia is a mucilage of Gleditsia triacanthos L.
6. Composition selon l'une quelconque des revendica¬ tions 2 à 5, caractérisée en ce que le mucilage est obtenu à partir de graines de Gleditsia. 6. Composition according to any one of revendica ¬ tions 2 to 5, characterized in that the mucilage is obtained from Gleditsia seeds.
7. Composition selon la revendication 6, caractérisée en ce que le mucilage est sous forme d'extrait sec.  7. Composition according to claim 6, characterized in that the mucilage is in the form of dry extract.
8. Composition selon l'une quelconque des revendica¬ tions 2 à 7, caractérisée en ce qu'elle est sous forme de lotion concentrée, gel, émulsion, baume, masque, pommade, nanocapsules , ou liposomes. 8. Composition according to any one of revendica ¬ tions 2 to 7, characterized in that it is in the form of concentrated lotion, gel, emulsion, balm, mask, ointment, nanocapsules, or liposomes.
9. Composition selon l'une quelconque des revendica¬ tions 2 à 8, caractérisée en ce qu'elle comprend de 1 à 15% en poids de mucilage de Gleditsia par rapport au poids total de la composition. 9. Composition according to any one of revendica ¬ tions 2 to 8, characterized in that it comprises 1 to 15% by weight of Gleditsia mucilage relative to the total weight of the composition.
10. Composition selon l'une quelconque des revendica¬ tions 2 à 9, caractérisée en ce qu'elle comprend en outre un ou plusieurs actifs secondaires choisis parmi un agent lipolytique complémentaire, un agent veinotonique, des polyphénols de cacao, ou un agent restructurant. 10. A composition according to any one of revendica ¬ tions 2 to 9, characterized in that it further comprises one or more secondary active agents selected from a complementary lipolytic agent, a venotonic agent, cocoa polyphenols, or a restructuring agent .
11. Composition selon la revendication 10, caractérisée en ce que l'agent lipolytique complémentaire est choisi parmi les bases xanthiques, des extraits d'algues, des extraits de lierre, des extraits de Coleus, des silanols, l'huile de chaulmoogra, et des guggulipides .  11. Composition according to claim 10, characterized in that the complementary lipolytic agent is selected from xanthine bases, extracts of algae, extracts of ivy, extracts of Coleus, silanols, oil of chaulmoogra, and guggulipids.
12. Composition selon la revendication 10, caractérisée en ce que l'agent veinotonique est choisi parmi la ruscogénine, l'escine, 1 ' hédéragénine, le Ginkgo biloba et la troxérutine .  12. Composition according to claim 10, characterized in that the venotonic agent is chosen from ruscogenin, escin, hederagenin, Ginkgo biloba and troxerutin.
13. Composition selon la revendication 12, caractérisée en ce qu'elle comprend entre 1 et 15% en poids de mucilage de Gleditsia et entre 0,05 et 1% en poids d'agent veinotonique, par rapport au poids total de la composition.  13. Composition according to claim 12, characterized in that it comprises between 1 and 15% by weight of Gleditsia mucilage and between 0.05 and 1% by weight of venotonic agent, relative to the total weight of the composition.
14. Procédé cosmétique non thérapeutique pour le traitement et la prévention des surcharges adipeuses et de la cellulite de la peau, consistant à appliquer sur les zones de la peau concernées une composition contenant une quantité efficace de la composition topique selon l'une quelconque des revendications 2 à 13.  14. A non-therapeutic cosmetic method for the treatment and prevention of adipose overloads and cellulite of the skin, comprising applying to the areas of the skin concerned a composition containing an effective amount of the topical composition according to any one of the claims. 2 to 13.
15. Utilisation cosmétique du mucilage de Gleditsia dans une composition topique amincissante.  15. Cosmetic use of Gleditsia mucilage in a topical slimming composition.
PCT/FR2012/050747 2011-04-11 2012-04-05 Gleditsia composition for treating excess fat WO2012140352A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1153127A FR2973698B1 (en) 2011-04-11 2011-04-11 GLEDITSIA - BASED COMPOSITION FOR TREATING ADDITIONAL OVERLOADS.
FR1153127 2011-04-11

Publications (2)

Publication Number Publication Date
WO2012140352A2 true WO2012140352A2 (en) 2012-10-18
WO2012140352A3 WO2012140352A3 (en) 2013-10-03

Family

ID=46052821

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2012/050747 WO2012140352A2 (en) 2011-04-11 2012-04-05 Gleditsia composition for treating excess fat

Country Status (2)

Country Link
FR (1) FR2973698B1 (en)
WO (1) WO2012140352A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB950997A (en) 1961-12-22 1964-03-04 Mauvernay Roland Yves Mucilage
FR1602259A (en) 1965-02-01 1970-11-02 Process for the prepn. of a compn. contg. extracts of Gleditsia triocanthos (I) by filtering extracts obtained using boiling water with the aid of filter aids
FR2490492A1 (en) 1980-09-22 1982-03-26 Riker Laboratories Inc Compsns. for treating cellulitis - contg. xanthine base and seaweed extract
FR2639541A1 (en) 1988-11-29 1990-06-01 Fabre Pierre Cosmetique TOPICAL SLIMMERS CONTAINING CARBOXYLIC CARBOXYLIC DERIVATIVES DERIVED FROM ORGANIC BASES AND PREPARATIONS USEFUL IN THE TREATMENT OF CELLULITE
WO2006045932A2 (en) 2004-10-22 2006-05-04 Laboratoire Nuxe Novel use of chaulmoogra oil and guggulipids in therapeutics and cosmetics
WO2008009813A2 (en) 2006-07-20 2008-01-24 Laboratoire Nuxe Use of an extract of gleditsia in cosmetics and in dermatology

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2067649A5 (en) * 1969-11-12 1971-08-20 Gonzales Jesus Galacto mannanes for hair decurling
FR2669537B1 (en) * 1990-11-28 1993-02-19 Oreal SLIMMING COMPOSITION BASED ON ALPHA-2-BLOCKERS.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB950997A (en) 1961-12-22 1964-03-04 Mauvernay Roland Yves Mucilage
FR1602259A (en) 1965-02-01 1970-11-02 Process for the prepn. of a compn. contg. extracts of Gleditsia triocanthos (I) by filtering extracts obtained using boiling water with the aid of filter aids
FR2490492A1 (en) 1980-09-22 1982-03-26 Riker Laboratories Inc Compsns. for treating cellulitis - contg. xanthine base and seaweed extract
FR2639541A1 (en) 1988-11-29 1990-06-01 Fabre Pierre Cosmetique TOPICAL SLIMMERS CONTAINING CARBOXYLIC CARBOXYLIC DERIVATIVES DERIVED FROM ORGANIC BASES AND PREPARATIONS USEFUL IN THE TREATMENT OF CELLULITE
WO2006045932A2 (en) 2004-10-22 2006-05-04 Laboratoire Nuxe Novel use of chaulmoogra oil and guggulipids in therapeutics and cosmetics
WO2008009813A2 (en) 2006-07-20 2008-01-24 Laboratoire Nuxe Use of an extract of gleditsia in cosmetics and in dermatology

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
0. FOUSSARD-BLANPIN ET AL.: "Annales Pharmaceutiques Françaises", vol. 27, 1969, pages: 257 - 259
BEAUCHESNE ET AL., PHYSIOLOGIA PLANTARUM, vol. 16, 1963
R.K. RAKHMANBERDYEVA ET AL., MEDICINAL AND AROMATIC PLANTS ABSTRACTS, vol. 25, no. 1, February 2003 (2003-02-01)
Y. YAMAMOTO ET AL., BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, vol. 64, no. 10, October 2000 (2000-10-01), pages 2165 - 2171

Also Published As

Publication number Publication date
WO2012140352A3 (en) 2013-10-03
FR2973698B1 (en) 2014-04-11
FR2973698A1 (en) 2012-10-12

Similar Documents

Publication Publication Date Title
WO2012172199A1 (en) Composition based on camellia japonica and polygonum hydropiper for protecting the skin
EP1768684B1 (en) Composition comprising a blue lotus extract for the treatment of facial uncontrolled muscular contractions
EP1811953B1 (en) Novel use of chaulmoogra oil and guggulipids in therapeutics and cosmetics
FR2907338A1 (en) Use of ferulic acid, its salts and/or derivatives as lipolytic agent to prepare a cosmetic and/or pharmaceutical composition to prevent and/or treat the adipose overloads and/or cellulitis, by systemic and/or local administration
EP2291173B1 (en) Combination of passion flower and alkanet extracts for use in cosmetics
EP2046356B1 (en) Use of an extract of gleditsia in cosmetics and in dermatology
EP2699227B1 (en) Plant extract complex for skin protection
EP3052198B1 (en) Oily composition comprising an extract of hemerocallis and its use
FR2885300A1 (en) Topical cosmetic and/or dermatological composition useful for skin protection comprises an araucaria seed extract
EP1879539B1 (en) Skin protective composition based on araucaria grain extracts
WO2012140352A2 (en) Gleditsia composition for treating excess fat
EP2811977B1 (en) Use of an apple tree leaf extract in a cosmetic skin-firming composition
FR2885052A1 (en) Use of a maca extract (Lepidium meyenii) for the preparation a dermatological medicament for topical use to prevent and treat the deficiency of cutaneous microcirculation
FR2876909A1 (en) Cosmetic and/or pharmaceutical composition, to prevent or treat adipose overloads and cellulitis, comprises a combination of one or more xanthinic bases and chaulmoogra oil and/or its components
WO2014001465A2 (en) Soothing topical composition containing paeonia and nymphaea extracts
WO2012140351A2 (en) Caffeine and triacanthine composition for treating excess fat
FR3003170A1 (en) USE OF AN EXTRACT OF WATER JACINTHE FOR MOISTURIZING THE SKIN
FR2876912A1 (en) Use of guggulipids and/or Z-guggulsterone and E-guggulsterone to prepare a cosmetic or pharmaceutical composition for the treatment and prevention of fat accumulation and cellulitis
WO2012172200A1 (en) Composition based on samanea saman for protecting the skin
FR2871380A1 (en) Topical cosmetic and/or dermatological composition, used to fight against signs of cutaneous ageing and to prevent/treat uncontrolled facial muscular contractions, comprises blue lotus extract
FR2885049A1 (en) Topical cosmetic and/or dermatological composition, useful to protect the skin and to fight against the climatic and environmental effect, comprises a seed extract of Araucaria
EP2849720A2 (en) Use of a chaste tree extract for preparing a cosmetic and/or dermatological composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12720253

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12720253

Country of ref document: EP

Kind code of ref document: A2